CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 376 enrolled
Drug / intervention
Chantix +2 moredrug
Likely dose
Nicotine patches 21 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01806779
NCT01806779Phase 2Completed
CompareCT.gov

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Duke University·interventional·Posted Mar 7, 2013·Updated Jan 18, 2016

In Brief

A Phase 2 clinical trial evaluating Chantix, Zyban, and 1 other intervention for Nicotine Dependence. Completed, enrolled 376 participants across 4 sites.

Detailed Summary

Previous results from the investigators' Center have shown that combination treatment with Chantix and Zyban is more successful in helping men quit smoking. The investigators hope to replicate these findings with this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Philip Morris USA, Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 7, 2013
Enrollment StartMar 1, 2013
Primary CompletionDec 1, 2014
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.3 years ago

Interventions

Chantixdrug

Zybandrug

Nicotine patchesdrug

All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.